Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | PIK3CA exon21 |
| Therapy | Aspirin |
| Indication/Tumor Type | rectum cancer |
| Response Type | sensitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| PIK3CA exon21 | rectum cancer | sensitive | Aspirin | Guideline | Actionable | Aspirin is included in guidelines as adjuvant therapy (category 2A) for patients with advanced rectal cancer harboring PIK3CA exon 21 (reported as exon 20) mutations, including hotspot mutations occurring at Y1021, M1043, N1044, and H1047, and other somatic mutations affecting the PI3K pathway genes PIK3CA, PIK3R1, or PTEN (NCCN.org). | detail... |
| PubMed Id | Reference Title | Details |
|---|---|---|
| NCCN.org | Full reference... |